Veracyte (VCYT) Stock Price, News, Quotes-Moomoo

US Stock MarketDetailed Quotes

VCYT Veracyte

Watchlist

38.195
-0.746-1.91%

Trading Nov 22 10:33 ET

2.96BMarket Cap-293803P/E (TTM)

Intraday

5D
Daily
Weekly
Monthly
1Q
1Y

Trade Overview

Unit: --

Capital Trend

IntradayDayWeekMonth

No Data

News

Veracyte Is Maintained at Underweight by Morgan Stanley
Dow JonesNov 18 10:41 ET · Ratings
Veracyte Price Target Raised to $28.00/Share From $26.00 by Morgan Stanley
Dow JonesNov 18 10:41 ET · Ratings
Express News | Veracyte Inc : Morgan Stanley Raises Target Price to $28 From $26
ReutersNov 18 05:21 ET
Sell Rating on Veracyte: Strong Performance Overshadowed by Limited Immediate Upside
TipRanksNov 18 05:11 ET · Ratings
Wolfe Research Initiates Veracyte(VCYT.US) With Buy Rating, Announces Target Price $50
Moomoo NewsNov 15 06:34 ET · Ratings
Veracyte Initiated With an Outperform at Wolfe on Growth, Margin Potential
TipRanksNov 15 06:10 ET · Ratings

Comments

Stock_Drift

Sep 15 09:56

$Veracyte (VCYT.US)$

ClydePeternuts

Sep 12 02:17

Cathie Wood and Ark Invest's trade activity from today 9/10
$ARK Innovation ETF (ARKK.US)$ :
Bought $Advanced Micro Devices (AMD.US)$ $DraftKings (DKNG.US)$ $Tempus AI (TEM.US)$
Sold $Unity Software (U.US)$ $Palantir (PLTR.US)$ $Twist Bioscience (TWST.US)$ $Veracyte (VCYT.US)$
By the way..
Palantir $PLTR is on fire this year
It's up over 109% YTD, just got included in the S&P500, and today Bank of America raised their price target to $50 a share
D. E. Shaw owns almost $500 million worth of shares, more than any...

Moomoo AI

Feb 24 08:25

Analysts are slightly more optimistic about Veracyte's losses per share, but expect its revenue growth to slow down substantially compared to its historical 29% growth rate. The wider industry is expected to outpace Veracyte.

Veracyte, Inc. (NASDAQ:VCYT) Just Released Its Annual Results And Analysts Are Updating Their Estimates

Moomoo AI

Oct 28, 2023 08:07

The absence of any insider transactions in the past three months doesn't reveal much. Low insider ownership and previous insider selling at Veracyte sparks less enthusiasm. Investors should be aware of potential risks associated with the company.